FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022138322> ?p ?o ?g. }

• W2022138322 endingPage "125" @default.
• W2022138322 startingPage "117" @default.
• W2022138322 abstract "Objectives:Docetaxel and paclitaxel show significant clinical activity in metastatic breast cancer (MBC) and have been approved for MBC by the U.S. Food and Drug Administration, but it is still unclear whether a paclitaxel-based regimen improves outcomes over a docetaxel-based regimen in patients with MBC. We therefore performed a meta-analysis of randomized controlled trials to compare the safety and efficacy of these two regimens in MBC.Methods:We systematically searched for randomized controlled trials that comparing paclitaxel-based with docetaxel-based regimens in patients with MBC in PubMed (up to January 2012), Embase (1980 to January 2012), and the Cochrane databases (up to January 2012). Abstracts presented at conferences (up to January 2011) were also searched. Data were extracted from the studies by two independent reviewers. The meta-analysis was performed by Stata version 12.0 software (Stata Corporation, College Station, TX, USA).Results:Seven eligible trials involving 1694 patients with MBC were selected. Our results showed that a paclitaxel-based regimen was comparable to a docetaxel-based regimen for MBC patients in terms of OS (HR: 0.87, 95% CI: 0.60–1.27, p = 0.48), PFS (HR: 0.76, 95% CI: 0.58–1.00, p = 0.052), TTP (HR: 1.13, 95% CI: 0.81–1.58, p = 0.46), and ORR (RR: 1.01, 95% CI: 0.88–1.15, p = 0.92), but fewer grade 3 or 4 adverse events including anemia (RR: 0.64, 95% CI: 0.44–0.94, p = 0.023), neutropenia (RR: 0.74, 95% CI: 0.58–0.93, p = 0.011), febrile neutropenia (RR: 0.38, 95% CI: 0.15–0.96, p = 0.041), thrombopenia (RR: 0.62, 95% CI: 0.41–0.96, p = 0.033), mucositis (RR: 0.082, 95% CI: 0.025–0.27, p < 0.001), diarrhea (RR: 0.19, 95% CI: 0.081–0.47, p < 0.001) and fatigue (RR: 0.43, 95% CI: 0.20–0.96, p = 0.039) were observed in the paclitaxel-based regimen. However, limitations of our study needed to be considered when interpreting these results: our study was a meta-analysis of published data, and there was significant heterogeneity among included trials. Potential publication bias might also exist.Conclusion:The present systematic review and meta-analysis demonstrates that both taxane-based regimens have comparable efficacy for patients with MBC, and the paclitaxel-based regimen is associated with less toxicity and better tolerability, especially in older patients and when used in weekly regimens." @default.
• W2022138322 created "2016-06-24" @default.
• W2022138322 creator A5003816686 @default.
• W2022138322 creator A5004597656 @default.
• W2022138322 creator A5029153524 @default.
• W2022138322 creator A5035263099 @default.
• W2022138322 creator A5056438877 @default.
• W2022138322 creator A5059865856 @default.
• W2022138322 creator A5068938480 @default.
• W2022138322 creator A5089019392 @default.
• W2022138322 date "2012-12-26" @default.
• W2022138322 modified "2023-09-28" @default.
• W2022138322 title "Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials" @default.
• W2022138322 cites W1563102200 @default.
• W2022138322 cites W1566131907 @default.
• W2022138322 cites W1596105818 @default.
• W2022138322 cites W1828224642 @default.
• W2022138322 cites W1964435302 @default.
• W2022138322 cites W1966953116 @default.
• W2022138322 cites W1973471242 @default.
• W2022138322 cites W1982967647 @default.
• W2022138322 cites W2011223682 @default.
• W2022138322 cites W2014212535 @default.
• W2022138322 cites W2024970829 @default.
• W2022138322 cites W2026037612 @default.
• W2022138322 cites W2031520489 @default.
• W2022138322 cites W2036045878 @default.
• W2022138322 cites W2050685336 @default.
• W2022138322 cites W2053703910 @default.
• W2022138322 cites W2057550630 @default.
• W2022138322 cites W2059539152 @default.
• W2022138322 cites W2067146266 @default.
• W2022138322 cites W2075642745 @default.
• W2022138322 cites W2086000565 @default.
• W2022138322 cites W2114614279 @default.
• W2022138322 cites W2117972559 @default.
• W2022138322 cites W2128941584 @default.
• W2022138322 cites W2130373334 @default.
• W2022138322 cites W2134338262 @default.
• W2022138322 cites W2136791645 @default.
• W2022138322 cites W2143989581 @default.
• W2022138322 cites W2327409371 @default.
• W2022138322 cites W2416394834 @default.
• W2022138322 cites W3004533979 @default.
• W2022138322 doi "https://doi.org/10.1185/03007995.2012.756393" @default.
• W2022138322 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23216340" @default.
• W2022138322 hasPublicationYear "2012" @default.
• W2022138322 type Work @default.
• W2022138322 sameAs 2022138322 @default.
• W2022138322 citedByCount "34" @default.
• W2022138322 countsByYear W20221383222014 @default.
• W2022138322 countsByYear W20221383222015 @default.
• W2022138322 countsByYear W20221383222016 @default.
• W2022138322 countsByYear W20221383222017 @default.
• W2022138322 countsByYear W20221383222018 @default.
• W2022138322 countsByYear W20221383222019 @default.
• W2022138322 countsByYear W20221383222020 @default.
• W2022138322 countsByYear W20221383222021 @default.
• W2022138322 countsByYear W20221383222022 @default.
• W2022138322 countsByYear W20221383222023 @default.
• W2022138322 crossrefType "journal-article" @default.
• W2022138322 hasAuthorship W2022138322A5003816686 @default.
• W2022138322 hasAuthorship W2022138322A5004597656 @default.
• W2022138322 hasAuthorship W2022138322A5029153524 @default.
• W2022138322 hasAuthorship W2022138322A5035263099 @default.
• W2022138322 hasAuthorship W2022138322A5056438877 @default.
• W2022138322 hasAuthorship W2022138322A5059865856 @default.
• W2022138322 hasAuthorship W2022138322A5068938480 @default.
• W2022138322 hasAuthorship W2022138322A5089019392 @default.
• W2022138322 hasConcept C121608353 @default.
• W2022138322 hasConcept C126322002 @default.
• W2022138322 hasConcept C143998085 @default.
• W2022138322 hasConcept C168563851 @default.
• W2022138322 hasConcept C197934379 @default.
• W2022138322 hasConcept C2775930923 @default.
• W2022138322 hasConcept C2776694085 @default.
• W2022138322 hasConcept C2777063308 @default.
• W2022138322 hasConcept C2777292972 @default.
• W2022138322 hasConcept C2781190966 @default.
• W2022138322 hasConcept C2781413609 @default.
• W2022138322 hasConcept C530470458 @default.
• W2022138322 hasConcept C71924100 @default.
• W2022138322 hasConcept C95190672 @default.
• W2022138322 hasConceptScore W2022138322C121608353 @default.
• W2022138322 hasConceptScore W2022138322C126322002 @default.
• W2022138322 hasConceptScore W2022138322C143998085 @default.
• W2022138322 hasConceptScore W2022138322C168563851 @default.
• W2022138322 hasConceptScore W2022138322C197934379 @default.
• W2022138322 hasConceptScore W2022138322C2775930923 @default.
• W2022138322 hasConceptScore W2022138322C2776694085 @default.
• W2022138322 hasConceptScore W2022138322C2777063308 @default.
• W2022138322 hasConceptScore W2022138322C2777292972 @default.
• W2022138322 hasConceptScore W2022138322C2781190966 @default.
• W2022138322 hasConceptScore W2022138322C2781413609 @default.
• W2022138322 hasConceptScore W2022138322C530470458 @default.
• W2022138322 hasConceptScore W2022138322C71924100 @default.
• W2022138322 hasConceptScore W2022138322C95190672 @default.
• W2022138322 hasIssue "2" @default.

• next